Clover Health sets results date. Deutsche Bank sets USD 6.00 target for Clover Health stock
Published on 10/08/2026 at 15:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Clover Health (US18914F1030) was trading at EUR 4.10 at Lang & Schwarz on October 8, 2026 at 2:40 p.m. CEST, plus 0.49 percent versus the prior close. The company set its third-quarter 2026 reporting date for November 4, 2026, while Deutsche Bank set a USD 6.00 price target on September 10, 2026. Clover Health published the reporting date, and Yahoo Finance reported the analyst action.
Three events shape the setup
On August 5, 2026, Clover Health reported second-quarter revenue of USD 743.20 million, up 55.60 percent from USD 477.60 million a year earlier, and GAAP net income of USD 28.00 million versus a USD 10.60 million loss. Yahoo Finance also reported Medicare Advantage membership of 157,309, up 48.00 percent year over year.
On September 10, 2026, Deutsche Bank initiated coverage with a Buy rating and a USD 6.00 target, while MarketBeat reported a Hold consensus and a USD 4.75 average target. On October 7, 2026, Clover Health announced the November 4 results date and a 5:00 p.m. Eastern Time webcast. Clover Health confirmed both details.
What does the results date change?
The November 4 release will test whether the second-quarter growth rate can continue into the third quarter. Management's 2026 outlook calls for total revenue of USD 2.92 billion to USD 3.00 billion, adjusted EBITDA of USD 70.00 million to USD 85.00 million, and GAAP net income of USD 20.00 million to USD 35.00 million. Yahoo Finance reported that the revenue outlook was raised from USD 2.81 billion to USD 2.92 billion, while the earlier net income outlook topped out at USD 20.00 million.
Next date and market context
Clover Health's next scheduled event is the third-quarter results release on November 4, 2026, followed by the webcast at 5:00 p.m. Eastern Time. The combination of USD 28.00 million in second-quarter GAAP net income and the new USD 20.00 million to USD 35.00 million full-year range gives the upcoming release a clear profitability test.
Euro quote remains near the yearly range
CLOV was trading at EUR 4.10 at Lang & Schwarz on October 8, 2026 at 2:40 p.m. CEST, plus 0.49 percent versus the Lang & Schwarz prior close of EUR 4.08. The primary listing is Nasdaq, where the finance quote showed USD 4.56 on October 7, 2026, against a 52-week range of USD 1.58 to USD 5.59 and market capitalization of USD 2.4 billion.
The further course of trading is shown by the continuously updated real-time quote of Clover Health stock.
Clover Health stock facts
- Company: Clover Health Investments, Corp.
- ISIN: US18914F1030
- Ticker: CLOV
- Primary exchange: Nasdaq
- Price Lang & Schwarz as of October 8, 2026, 2:40 p.m. CEST: EUR 4.10
- Change versus prior close: plus 0.49 percent
- Prior close Lang & Schwarz October 7, 2026: EUR 4.08
- Market capitalization: USD 2.4 billion as of October 7, 2026
- 52-week range: USD 1.58-5.59 as of October 7, 2026
- Sector / Industry: Healthcare / Medical - Healthcare Plans
- Next earnings date: November 4, 2026
Market context: Market report Nasdaq Composite.
